Literature DB >> 32344015

Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Surendra K Shukla1, Spas D Markov1, Kuldeep S Attri1, Enza Vernucci1, Ryan J King1, Aneesha Dasgupta1, Paul M Grandgenett1, Michael A Hollingsworth1, Pankaj K Singh1, Fang Yu2, Kamiya Mehla3.   

Abstract

Incidence of cachexia is highly prevalent in pancreatic ductal adenocarcinoma (PDAC); advanced disease stage directly correlates with decreased muscle and fat mass in PDAC patients. The pancreatic tumor microenvironment is central to the release of systemic factors that govern lipolysis, proteolysis, and muscle and fat degeneration leading to the cachectic phenotype in cancer patients. The current study explores the role of macrophages, a key immunosuppressive player in the pancreatic tumor microenvironment, in regulating cancer cachexia. We observed a negative correlation between CD163-positive macrophage infiltration and muscle-fiber cross sectional area in human PDAC patients. To investigate the role of macrophages in myodegeneration, we utilized conditioned media transplant assays and orthotopic models of PDAC-induced cachexia in immune-competent mice with and without macrophage depletion. We observed that macrophage-derived conditioned medium, in combination with tumor cell-conditioned medium, promoted muscle atrophy through STAT3 signaling. Furthermore, macrophage depletion attenuated systemic inflammation and muscle wasting in pancreatic tumor-bearing mice. Targeting macrophage-mediated STAT3 activation or macrophage-derived interleukin-1 alpha or interleukin-6 diminished myofiber atrophy. Taken together, the current study identified the critical association between macrophages and cachexia phenotype in pancreatic cancer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer cachexia; IL-6; Macrophages; Pancreatic cancer; STAT3

Mesh:

Substances:

Year:  2020        PMID: 32344015      PMCID: PMC7286478          DOI: 10.1016/j.canlet.2020.04.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  84 in total

1.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.

Authors:  M D Gomes; S H Lecker; R T Jagoe; A Navon; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 3.  Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

Authors:  Erin E Talbert; Denis C Guttridge
Journal:  Semin Cell Dev Biol       Date:  2015-09-16       Impact factor: 7.727

4.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

5.  Cachexia worsens prognosis in patients with resectable pancreatic cancer.

Authors:  Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  J Gastrointest Surg       Date:  2008-03-18       Impact factor: 3.452

6.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

7.  Inhibition of interleukin-6 decreases atrogene expression and ameliorates tail suspension-induced skeletal muscle atrophy.

Authors:  Mitsutaka Yakabe; Sumito Ogawa; Hidetaka Ota; Katsuya Iijima; Masato Eto; Yasuyoshi Ouchi; Masahiro Akishita
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

Review 8.  The JAK/STAT Pathway in Skeletal Muscle Pathophysiology.

Authors:  Viviana Moresi; Sergio Adamo; Libera Berghella
Journal:  Front Physiol       Date:  2019-04-30       Impact factor: 4.566

Review 9.  Pancreatic cancer cachexia: a review of mechanisms and therapeutics.

Authors:  Carlyn R Tan; Patrick M Yaffee; Laith H Jamil; Simon K Lo; Nicholas Nissen; Stephen J Pandol; Richard Tuli; Andrew E Hendifar
Journal:  Front Physiol       Date:  2014-03-03       Impact factor: 4.566

10.  Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy, Increases Anti-tumor T Cell Activity and Reduces Treatment-Induced Cachexia.

Authors:  Lelinh Duong; Hannah G Radley-Crabb; Joanne K Gardner; Federica Tomay; Danielle E Dye; Miranda D Grounds; Fiona J Pixley; Delia J Nelson; Connie Jackaman
Journal:  Front Genet       Date:  2018-11-06       Impact factor: 4.599

View more
  20 in total

1.  Preclinical Models for Studying the Impact of Macrophages on Cancer Cachexia.

Authors:  Spas Dimitrov Markov; Daisy Gonzalez; Kamiya Mehla
Journal:  Curr Protoc Pharmacol       Date:  2020-12

Review 2.  The Molecular Basis and Therapeutic Potential of Leukemia Inhibitory Factor in Cancer Cachexia.

Authors:  Ruijiang Zeng; Chang Tong; Xiangyang Xiong
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

3.  IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer.

Authors:  Spas Dimitrov Markov; Thomas C Caffrey; Kelly A O'Connell; James A Grunkemeyer; Simon Shin; Ryan Hanson; Prathamesh P Patil; Surendra K Shukla; Daisy Gonzalez; Ayrianne J Crawford; Krysten E Vance; Ying Huang; Kirsten C Eberle; Prakash Radhakrishnan; Paul M Grandgenett; Pankaj K Singh; Ragupathy Madiyalakan; Tracy R Daniels-Wells; Manuel L Penichet; Christopher F Nicodemus; Jill A Poole; Elizabeth M Jaffee; Michael A Hollingsworth; Kamiya Mehla
Journal:  Mol Cancer Ther       Date:  2021-10-08       Impact factor: 6.009

4.  Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.

Authors:  Mangala Hegde; Uzini Devi Daimary; Sosmitha Girisa; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-06

5.  JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.

Authors:  Scott E Mulder; Aneesha Dasgupta; Ryan J King; Jaime Abrego; Kuldeep S Attri; Divya Murthy; Surendra K Shukla; Pankaj K Singh
Journal:  Cancer Lett       Date:  2020-07-28       Impact factor: 8.679

6.  Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting.

Authors:  Calvin L Cole; John F Bachman; Jian Ye; Joseph Murphy; Scott A Gerber; Christopher A Beck; Brendan F Boyce; Gowrishankar Muthukrishnan; Joe V Chakkalakal; Edward M Schwarz; David Linehan
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-05-07       Impact factor: 12.910

7.  Mathematical Model of Muscle Wasting in Cancer Cachexia.

Authors:  Suzan Farhang-Sardroodi; Kathleen P Wilkie
Journal:  J Clin Med       Date:  2020-06-28       Impact factor: 4.241

Review 8.  Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism.

Authors:  Volker Schirrmacher
Journal:  Biomedicines       Date:  2020-11-22

9.  Preclinical Investigation of Alpinetin in the Treatment of Cancer-Induced Cachexia via Activating PPARγ.

Authors:  Yujie Zhang; Yuxin Zhang; Yichen Li; Li Zhang; Shiying Yu
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

10.  Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects.

Authors:  Jason Sadek; Derek T Hall; Bianca Colalillo; Amr Omer; Anne-Marie K Tremblay; Virginie Sanguin-Gendreau; William Muller; Sergio Di Marco; Marco Emilio Bianchi; Imed-Eddine Gallouzi
Journal:  EMBO Mol Med       Date:  2021-06-07       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.